title: Dabigatran efficacy-safety assessment for stroke prevention in patients with atrial fibrillation.
authors.forename: J W
authors.initials: JW
authors.lastname: Eikelboom
authors.forename: D J
authors.initials: DJ
authors.lastname: Quinlan
authors.forename: S J
authors.initials: SJ
authors.lastname: Connolly
authors.forename: R G
authors.initials: RG
authors.lastname: Hart
authors.forename: S
authors.initials: S
authors.lastname: Yusuf
mesh_terms: D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D001562:Benzimidazoles / Q000009:adverse effects / Q000627:therapeutic use*; D001777:Blood Coagulation / Q000187:drug effects*; D000069604:Dabigatran; D019317:Evidence-Based Medicine; D006801:Humans; D020300:Intracranial Hemorrhages / Q000139:chemically induced; D061214:Patient Safety; D018570:Risk Assessment; D012307:Risk Factors; D020521:Stroke / Q000097:blood / Q000209:etiology / Q000517:prevention & control*; D016896:Treatment Outcome; D015091:beta-Alanine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000925:Anticoagulants; D001562:Benzimidazoles; D015091:beta-Alanine; D000069604:Dabigatran